Cancer

Cancer

OSE Immunotherapeutics and FoRT Foundation Complete Enrollment in Combi-TED Clinical Trial Evaluating Tedopi in Combination with Nivolumab or Docetaxel for Non-Small Cell Lung Cancer

The phase 2 clinical trial, Combi-TED, has successfully completed the enrollment of 105 HLA-A2 positive patients with non-small cell lung cancer (NSCLC) to evaluate the efficacy of Tedopi, a neoepitope-based therapeutic cancer vaccine, in combination with either nivolumab or docetaxel. This trial is an open-label, randomized, three-arm study assessing the